Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-arginine Infusion on Sympathetic Nerve Activity in CKD Patients
NCT03982160Phase 4Active, not recruiting
- Sponsor
- The University of Texas at Arlington
- Start
- Feb 2018
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 4, randomised trial of arginine in chronic kidney disease (CKD) (2 arms), sponsored by The University of Texas at Arlington. Primary endpoint: Muscle sympathetic nerve activity at 30 minutes. Started Feb 2018; status: active, not recruiting.
02
Drugs
arginine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03982160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982160.